IS6766A - Pravastatin sodium, largely free of pravastatin lactone and epi-pravastatin, and mixtures containing it - Google Patents

Pravastatin sodium, largely free of pravastatin lactone and epi-pravastatin, and mixtures containing it

Info

Publication number
IS6766A
IS6766A IS6766A IS6766A IS6766A IS 6766 A IS6766 A IS 6766A IS 6766 A IS6766 A IS 6766A IS 6766 A IS6766 A IS 6766A IS 6766 A IS6766 A IS 6766A
Authority
IS
Iceland
Prior art keywords
pravastatin
epi
lactone
mixtures containing
largely free
Prior art date
Application number
IS6766A
Other languages
Icelandic (is)
Inventor
Keri Vilmos
Deak Lajos
Forgacs Ilona
Szabo Csaba
Edit Nagyne Arvai
Original Assignee
Teva Gyogyszergy βr Részvényt βrsas βg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Gyogyszergy βr Részvényt βrsas βg filed Critical Teva Gyogyszergy βr Részvényt βrsas βg
Publication of IS6766A publication Critical patent/IS6766A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6766A 2000-10-05 2003-04-01 Pravastatin sodium, largely free of pravastatin lactone and epi-pravastatin, and mixtures containing it IS6766A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Publications (1)

Publication Number Publication Date
IS6766A true IS6766A (en) 2003-04-01

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6766A IS6766A (en) 2000-10-05 2003-04-01 Pravastatin sodium, largely free of pravastatin lactone and epi-pravastatin, and mixtures containing it

Country Status (18)

Country Link
EP (1) EP1330245A4 (en)
JP (6) JP3737801B2 (en)
KR (1) KR20030059173A (en)
CN (1) CN1468098A (en)
AU (1) AU2002211462A1 (en)
CA (1) CA2422744A1 (en)
CZ (1) CZ20031166A3 (en)
HR (1) HRP20030347A2 (en)
HU (1) HUP0400913A2 (en)
IL (1) IL155194A0 (en)
IS (1) IS6766A (en)
MX (1) MXPA03002963A (en)
NO (1) NO20031532D0 (en)
NZ (1) NZ525631A (en)
PL (1) PL361230A1 (en)
SK (1) SK5232003A3 (en)
WO (1) WO2002030415A1 (en)
ZA (1) ZA200302313B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481674B1 (en) * 1999-11-30 2008-01-02 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
JP3881240B2 (en) * 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Method for recovering statin compounds from fermentation broth
AU779306B2 (en) 1999-12-14 2005-01-13 Teva Gyogyszergyar Reszvenytarsasag Novel forms of pravastatin sodium
CN1468098A (en) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (en) * 2000-10-16 2001-12-10 三共株式会社 How to purify pravastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051372A2 (en) 2003-11-24 2005-06-09 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Method of purifying pravastatin
BRPI0514189A (en) 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc statin pharmaceutical compositions and related treatment methods
ES2254028B1 (en) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. PROCEDURE FOR OBTAINING PRAVASTATIN SODIUM PURIFIED.
KR20070099034A (en) * 2005-02-25 2007-10-08 테바 파마슈티컬 인더스트리즈 리미티드 Process of purifying tadalafil
JP4813841B2 (en) * 2005-07-25 2011-11-09 キユーピー株式会社 Method for producing pravastatin sodium
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (en) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 Preparation method of high-purity pravastatin 1, 3-tetramethylbutylamine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (en) * 1973-09-29 1977-06-11
AT353409B (en) * 1975-02-07 1979-11-12 Glaxo Lab Ltd METHOD OF REMOVING CONTAMINATION FROM CLAVULANIC ACID OR THEIR SALT
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (en) * 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
JPS5889191A (en) * 1981-11-20 1983-05-27 Sankyo Co Ltd Preparation of 3-hydroxy-ml-236b derivative
JPS5890509A (en) * 1981-11-25 1983-05-30 Sankyo Co Ltd Composition for remedy of hypercholesterolemia
JPH01190661A (en) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk Purification of 4,4'-dihydroxydiphenylsulfone
JP2739328B2 (en) * 1988-09-14 1998-04-15 日本ケミファ株式会社 Purification method of benzimidazole compound
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (en) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd Optically active alpha-carbamoylalkanoic acid derivative and its production
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
WO1995027073A1 (en) * 1994-03-31 1995-10-12 Pfizer Inc. Process for natamycin recovery
EP0784605B1 (en) * 1995-08-03 2000-02-16 Dsm N.V. Selective process for the deacylation of acylated compounds
JPH09124655A (en) * 1995-11-01 1997-05-13 Sankyo Co Ltd New squalene synthase inhibition-active compound
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20070A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE
SI20072A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. PROCEDURE OF PREPARATION OF INHIBITORS OF HMG-CoA REDUCTASE
JP2000229855A (en) * 1998-12-07 2000-08-22 Satoshi Takebe Pravastatin sodium tablet
MXPA01007807A (en) * 1999-02-03 2003-06-04 Inst Drug Res Ltd Microbial process for preparing pravastatin.
HUP9902352A1 (en) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Process for producing pravastatin by microbiological way
JP3881240B2 (en) * 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Method for recovering statin compounds from fermentation broth
CN1468098A (en) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Also Published As

Publication number Publication date
HRP20030347A2 (en) 2005-04-30
ZA200302313B (en) 2004-03-25
WO2002030415A9 (en) 2002-10-31
PL361230A1 (en) 2004-10-04
MXPA03002963A (en) 2005-01-25
CN1468098A (en) 2004-01-14
JP2013128486A (en) 2013-07-04
EP1330245A4 (en) 2004-10-20
JP3737801B2 (en) 2006-01-25
CA2422744A1 (en) 2002-04-18
NO20031532L (en) 2003-04-04
WO2002030415A1 (en) 2002-04-18
JP2004510817A (en) 2004-04-08
JP2009268479A (en) 2009-11-19
NO20031532D0 (en) 2003-04-04
AU2002211462A1 (en) 2002-04-22
HUP0400913A2 (en) 2006-11-28
NZ525631A (en) 2005-05-27
IL155194A0 (en) 2003-11-23
CZ20031166A3 (en) 2004-04-14
JP2015212300A (en) 2015-11-26
EP1330245A1 (en) 2003-07-30
JP2006036781A (en) 2006-02-09
KR20030059173A (en) 2003-07-07
SK5232003A3 (en) 2004-06-08
JP2005013238A (en) 2005-01-20

Similar Documents

Publication Publication Date Title
IS6766A (en) Pravastatin sodium, largely free of pravastatin lactone and epi-pravastatin, and mixtures containing it
DK1329456T3 (en) Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
ITMI20011489A0 (en) STABILIZING MIXTURES
ID30590A (en) ONCE USE SHORT TYPE OF SHORT-PANTS
ID30187A (en) DONGKRAK KIND OF PANTAGRAF
PT1250321E (en) COMPOSITION OF GLIBURIDA
ATE275938T1 (en) STABLE AND EFFECTIVE SOFT SOLID PRODUCT
IS6021A (en) Pharmaceutical formulations containing citalopram
DE50103036D1 (en) O-SUBSTITUTED 6-METHYL-TRAMADOL DERIVATIVES
AR028070A1 (en) SYNTHESIS OF CYCLHEXENDIMETHANOL OR CYCLHEXANDIMETHANOL COMPOUNDS
NO20024354D0 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
NO20025474D0 (en) Benzofuran
NO20011703D0 (en) Capacitor of non-combustible and accident prevention type
IS6734A (en) Triazole derivatives and pharmaceutical compositions containing them
IS6857A (en) Pharmaceutical composition containing citalopram
GB2358859B (en) Synthesis of isosorbide-5-mononitrate and substituted analogues thereof
DE60124221D1 (en) MONOHYDRATE OF CIS-LITHIUM-CYANO-4-i3- (CYCLOPENTYLOY) -4-METHOXYPHENYLOCYCLOHEXANCARBOXYLATE
FI20000526A0 (en) Extinguishing arrangements of pre-insurance
FR2809403B1 (en) BACTERIOCIN ANTI-LISTERIA
UA4579S (en) DOSIMETER-RADIOMETER OF GAMMA-BETA-RADIATION
FI4458U1 (en) Smoke sauna
FR2810531B1 (en) TROPY OF COELIO-SURGERY
SE0004003D0 (en) Synthesis of FLG
FI4637U1 (en) Improved smoke sauna
HK1025474A2 (en) Frame structure of smoke extrator